Ekaterina Prokoshev/ Shutterstock.com
Big Pharma is looking for solutions to the COVID-19 pandemic wherever it can find them, so drug repurposing is more important than ever, as research lawyers Jakob Wested and John Liddicoat argue.
The repurposing of drugs that have been approved for treating other viruses has gained unprecedented media attention during the COVID-19 pandemic. Lawyers persistently criticise second medical use patent claims as pointless, yet pharmaceutical companies continue to obtain and litigate them. Second medical use patents are probably valuable only occasionally and if standing alone, they are an unstable foundation for a business model.
The EU regulatory system provides incentives for repurposing. When a drug is authorised for the first time, the authorisation holder receives eight years of data exclusivity that runs concurrently with ten years of market protection. These two exclusivities are often summarised as 8+2, with the 2 referring to the two years remaining of market protection (after the expiry of data protection).
There’s a specific incentive for companies to repurpose drugs: market protection will be extended to 11 years if, within eight years of authorisation, the drug is repurposed to treat a new indication that brings a significant clinical benefit compared to existing therapies.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at firstname.lastname@example.org.
If you have any technical issues please email tech support.
repurposing, drug, drugs, companies, COVID-19, incentives,Jakob Wested, John Liddicoat,, pharma, Epogen, Procrit, University of Cambridge